Prevalence of hepatic steatosis in women with polycystic ovary syndrome
Objective: Nonalcoholic fatty liver disease (NAFLD) and polycystic ovary syndrome (PCOS) both are known to be associated with insulin resistance and metabolic syndrome (MS). The aim of the study was to determine the presence of NAFLD and associated factors of hepatic steatosis in women with PCOS. Ma...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wolters Kluwer Medknow Publications
2013-01-01
|
| Series: | Journal of Human Reproductive Sciences |
| Subjects: | |
| Online Access: | http://www.jhrsonline.org/article.asp?issn=0974-1208;year=2013;volume=6;issue=1;spage=9;epage=14;aulast=Karoli |
| _version_ | 1818318892567625728 |
|---|---|
| author | Ritu Karoli Jalees Fatima Ashok Chandra Uma Gupta Faraz-ul Islam Gagandeep Singh |
| author_facet | Ritu Karoli Jalees Fatima Ashok Chandra Uma Gupta Faraz-ul Islam Gagandeep Singh |
| author_sort | Ritu Karoli |
| collection | DOAJ |
| description | Objective: Nonalcoholic fatty liver disease (NAFLD) and polycystic ovary syndrome (PCOS) both are known to be associated with insulin resistance and metabolic syndrome (MS). The aim of the study was to determine the presence of NAFLD and associated factors of hepatic steatosis in women with PCOS. Materials and Methods: A cross-sectional hospital based study of 54 women with PCOS and 55 healthy controls who were age and weight matched were included. Anthropometric parameters, biochemical and hormonal investigations were done in all the patients. Insulin resistance was calculated by Homeostasis model assessment (HOMA). Abdominal ultrasonography and biochemical tests were used to determine the presence of hepatic steatosis after excluding other causes liver disease. Results : Women with PCOS had a higher prevalence of hepatic steatosis (67% vs 25%, P = 0.001) MS (35% vs. 7%, P < 0.01) and elevated transaminases (31% vs. 7%, P = 0.03) than controls. All patients with PCOS and controls with MS had presence of hepatic steatosis. Age, BMI, waist-hip ratio, HOMA-IR, HDL and PCOS diagnosis were the factors associated with presence of hepatic steatosis. Conclusion : NAFLD is commonly present in women with PCOS in combination with other metabolic derangements. Evaluation for liver disease should be considered at an earlier age in women with PCOS, particularly those who have an evidence of MS. |
| first_indexed | 2024-12-13T10:00:26Z |
| format | Article |
| id | doaj.art-c44bb005a54842e9802026edde558345 |
| institution | Directory Open Access Journal |
| issn | 0974-1208 1998-4766 |
| language | English |
| last_indexed | 2024-12-13T10:00:26Z |
| publishDate | 2013-01-01 |
| publisher | Wolters Kluwer Medknow Publications |
| record_format | Article |
| series | Journal of Human Reproductive Sciences |
| spelling | doaj.art-c44bb005a54842e9802026edde5583452022-12-21T23:51:41ZengWolters Kluwer Medknow PublicationsJournal of Human Reproductive Sciences0974-12081998-47662013-01-016191410.4103/0974-1208.112370Prevalence of hepatic steatosis in women with polycystic ovary syndromeRitu KaroliJalees FatimaAshok ChandraUma GuptaFaraz-ul IslamGagandeep SinghObjective: Nonalcoholic fatty liver disease (NAFLD) and polycystic ovary syndrome (PCOS) both are known to be associated with insulin resistance and metabolic syndrome (MS). The aim of the study was to determine the presence of NAFLD and associated factors of hepatic steatosis in women with PCOS. Materials and Methods: A cross-sectional hospital based study of 54 women with PCOS and 55 healthy controls who were age and weight matched were included. Anthropometric parameters, biochemical and hormonal investigations were done in all the patients. Insulin resistance was calculated by Homeostasis model assessment (HOMA). Abdominal ultrasonography and biochemical tests were used to determine the presence of hepatic steatosis after excluding other causes liver disease. Results : Women with PCOS had a higher prevalence of hepatic steatosis (67% vs 25%, P = 0.001) MS (35% vs. 7%, P < 0.01) and elevated transaminases (31% vs. 7%, P = 0.03) than controls. All patients with PCOS and controls with MS had presence of hepatic steatosis. Age, BMI, waist-hip ratio, HOMA-IR, HDL and PCOS diagnosis were the factors associated with presence of hepatic steatosis. Conclusion : NAFLD is commonly present in women with PCOS in combination with other metabolic derangements. Evaluation for liver disease should be considered at an earlier age in women with PCOS, particularly those who have an evidence of MS.http://www.jhrsonline.org/article.asp?issn=0974-1208;year=2013;volume=6;issue=1;spage=9;epage=14;aulast=KaroliInsulin resistancemetabolic syndromenon-alcoholic fatty liver diseasepolycystic ovary syndrome |
| spellingShingle | Ritu Karoli Jalees Fatima Ashok Chandra Uma Gupta Faraz-ul Islam Gagandeep Singh Prevalence of hepatic steatosis in women with polycystic ovary syndrome Journal of Human Reproductive Sciences Insulin resistance metabolic syndrome non-alcoholic fatty liver disease polycystic ovary syndrome |
| title | Prevalence of hepatic steatosis in women with polycystic ovary syndrome |
| title_full | Prevalence of hepatic steatosis in women with polycystic ovary syndrome |
| title_fullStr | Prevalence of hepatic steatosis in women with polycystic ovary syndrome |
| title_full_unstemmed | Prevalence of hepatic steatosis in women with polycystic ovary syndrome |
| title_short | Prevalence of hepatic steatosis in women with polycystic ovary syndrome |
| title_sort | prevalence of hepatic steatosis in women with polycystic ovary syndrome |
| topic | Insulin resistance metabolic syndrome non-alcoholic fatty liver disease polycystic ovary syndrome |
| url | http://www.jhrsonline.org/article.asp?issn=0974-1208;year=2013;volume=6;issue=1;spage=9;epage=14;aulast=Karoli |
| work_keys_str_mv | AT ritukaroli prevalenceofhepaticsteatosisinwomenwithpolycysticovarysyndrome AT jaleesfatima prevalenceofhepaticsteatosisinwomenwithpolycysticovarysyndrome AT ashokchandra prevalenceofhepaticsteatosisinwomenwithpolycysticovarysyndrome AT umagupta prevalenceofhepaticsteatosisinwomenwithpolycysticovarysyndrome AT farazulislam prevalenceofhepaticsteatosisinwomenwithpolycysticovarysyndrome AT gagandeepsingh prevalenceofhepaticsteatosisinwomenwithpolycysticovarysyndrome |